Trials / Terminated
TerminatedNCT05317013
CBD in Postmenopausal Women With Osteopenia
A Randomized, Double-Blind, Placebo-Controlled, Repeated-Dose Study to Assess the Safety, Tolerability, and Preliminary Effects of CHI-554 in Postmenopausal Women With Osteopenia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Canopy Growth Corporation · Industry
- Sex
- Female
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBD | CBD |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2022-09-22
- Completion
- 2022-09-22
- First posted
- 2022-04-07
- Last updated
- 2022-09-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05317013. Inclusion in this directory is not an endorsement.